<DOC>
	<DOCNO>NCT00397215</DOCNO>
	<brief_summary>The present study design evaluate immunogenicity safety single double dose pandemic influenza candidate vaccine ( GSK1562902A ) , administer follow two-administration schedule ( 21 day apart ) adult 60 year age . The persistence influenza antibody also evaluate 24 month vaccination .</brief_summary>
	<brief_title>Evaluate Safety &amp; Immunogenicity Pandemic Influenza Vaccine ( GSK1562902A ) Adults Over 60 Years Age</brief_title>
	<detailed_description>The present study design evaluate immunogenicity safety single double dose candidate vaccine healthy elderly person . The candidate vaccine administer follow two-administration schedule ( 21 day apart ) adult 60 year age . The persistence H5N1 influenza antibody also evaluate two year vaccination ( neutralize antibody evaluate subset subject adjuvanted group ) . Single double dose H5N1 vaccine non-adjuvanted vaccine use comparator .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female age 61 year time first vaccination . Written inform consent obtain subject . Healthy subject subject well control underlying disease . Administration license MF59containing vaccine , e.g . Fluad™ Addigrip™ virosomebased influenza vaccine Inflexal V™ , InfectoVac Flu™ Invivac™ 20062007 influenza season . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration vaccine foreseen study protocol 30 day second vaccination H5N1 vaccine . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first administration study vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History chronic alcohol consumption and/or drug abuse . History hypersensitivity vaccine . History allergic disease reaction likely exacerbate component vaccine ( include egg thiomersal allergy ) . Acute clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Acute disease time enrolment . Serious chronic disease include medically significant chronic pulmonary , cardiovascular , renal , neurological , psychiatric metabolic disorder , determine medical history physical examination . Administration immunoglobulins and/or blood product within three month precede first vaccination study . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day prior first vaccination , plan use study period . Any condition , opinion investigator , prevents subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>H5N1</keyword>
	<keyword>influenza</keyword>
	<keyword>vaccine</keyword>
</DOC>